Moderna got some less than positive news yesterday.
This following Moderna shares hitting a record high Monday after the group published details of its phase 1 vaccine study that suggested at least eight of the 45 patients involved developed coronavirus antibodies in the weeks following the injection of it developing the drug, mRNA-127
The healthcare and pharmacy website, STAT News, published a report shortly after which questioned the study's sample size, the dearth of hard data, and the lack of a corresponding statement from the the National Institute for Allergy and Infectious Diseases, which partnered with Moderna in the phase 1 study.
More detailed results from a peer-reviewed study are expected later in the summer, but the Stat News report, as well as Moderna's decision to offer 17.6 million shares at $76 each following Monday's 20% surge to $80 a share, added to investor concerns and generated criticism from political leaders.
Another issue STAT noted is that while the Phase 1 trial included healthy volunteers aged 18 to 55, the ages of these eight people that developed the neutralizing antibodies are unknown.
And Anna Durbin, a vaccine researcher at Johns Hopkins University, noted that blood drawn for the study was taken just two weeks after patients received the vaccine.
Jim Cramer weighed in on STAT’s article on Moderna and what it means for the company going forward. His main takeaway? "Moderna suffers from premature explanation," Cramer said.
Watch More of the Latest Videos on TheStreet and Jim Cramer
- Jim Cramer: $35 'Magic Number' for Oil
- Jim Cramer: J.C. Penney Stock Will Never Come Back
- Jim Cramer: Nike Reopening Stores Is Exciting
- Moderna Rallies, But Here's Why Cramer Doesn't Trust Move Higher
- New York Governor Andrew Cuomo Advises Professional Sports Teams to Resume Games Without Fans; A Bid to Boost Sports